The ALK inhibitor lorlatinib could be used in first line treatment of ALK-rearranged non-small-cell lung cancer (NSCLC) because of its high efficacy against brain metastases, an Australian-led phase 3 trial has shown. An interim analysis of the CROWN trial, presented at ESMO Virtual Congress 2020 by Professor Ben Solomon, medical oncologist at the Peter MacCallum ...
ALK inhibitor suitable for first line therapy in NSCLC
By Michael Woodhead
24 Sep 2020